NFSG
RNTX

Newbridge Financial Services Group’s Rein Therapeutics RNTX Stock Holding History

Newbridge Financial Services Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101 Hold
97
– – ﹤0.01% 1198
2026
Q1 		$126 Buy
+97
New +$120 ﹤0.01% 1146
2025
Q2 		– Sell
-11,194
Closed -$19.8K – 1376
2025
Q1 		$19.8K Buy
+11,194
New +$23.5K ﹤0.01% 546
2024
Q4 		– Sell
-25,000
Closed -$88.5K – 1195
2024
Q3 		$88.5K Buy
+25,000
New +$66.8K 0.03% 205

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Newbridge Financial Services Group's RNTX Position: Q2 2026 in Review

Newbridge Financial Services Group held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 97 shares worth $101. The position accounts for ﹤0.01% of the portfolio, ranked #1198.

Newbridge Financial Services Group first reported a position in RNTX in Q3 2024 and has held it in 4 quarters since. The position peaked at $88.5K in Q3 2024. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Newbridge Financial Services Group held 97 shares of Rein Therapeutics worth $101 as of Q2 2026.
  • Newbridge Financial Services Group left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #1198 holding.
  • Newbridge Financial Services Group first reported a position in Rein Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Newbridge Financial Services Group's Rein Therapeutics position peaked at $88.5K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.